On July 16, Definium Therapeutics rose 5.5% in regular trading, trading at $46.5/share, with turnover of $24.58 million.

On the news front, multiple catalysts continue to support buying momentum. The company previously reported positive topline results from its pivotal Phase 3 EMERGE study of DT120 oral disintegrating tablet for Major Depressive Disorder, meeting the primary endpoint and all key secondary efficacy endpoints with statistically significant and clinically meaningful improvement over placebo. The company subsequently completed an $805 million capital raise with underwriters fully exercising the overallotment option. RBC Capital raised its price target from $36 to $57, maintaining an Outperform rating.

Adding sector tailwinds, Eli Lilly announced a $3.8 billion acquisition of AtaiBeckley at a 26% premium, deepening its neuroscience pipeline in psychedelic-based treatments. The deal explicitly referenced Definium Therapeutics as a peer developing a promising LSD-based approach for MDD, further validating the therapeutic space and investor interest in the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)